7 completed, 3 terminated, 3 unknown, 1 recruiting. 16 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 7, Terminated 3, Unknown 3, Recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 1 | 3 | Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Lung Disease: new trials by email Literature Review of Lung Disease trials Research Report on Lung Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Pfizer | 120 | 2026-06-30 | 2026-10-08 |
| NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biological NTLA-3001 - Lung Disease, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Intellia Therapeutics | 2024-11-20 | 2025-01-17 | |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC SHR-1210 - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 146 | 2017-05-03 | 2023-02-16 |
| Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit Neutrophil Activation Probe (NAP) - Lung Disease | Phase 2 | Completed | University of Edinburgh | 11 | 2016-12-01 | 2022-11-04 |
| Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders lipoaspiration, ADcSVF, Normal Saline IV - Lung Disease | Phase 1 / Phase 2 | Suspended | Healeon Medical Inc | 100 | 2016-10-01 | 2025-09-12 |
| Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease The Hospital2Home Service - Lung Disease | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 52 | 2011-10-01 | 2011-12-08 |
| Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis AZD5069, Placebo - Bronchiectasis, Lung Disease | Phase 2 | Completed | AstraZeneca | 83 | 2011-02-01 | 2015-10-08 |
| Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD) AZD2423, AZD2423 Placebo - Chronic Obstructive Pulmonary Disease, Lung Disease | Phase 2 | Completed | AstraZeneca | 71 | 2010-10-01 | 2015-04-10 |
| AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) AZD2423, Placebo to AZD2423 - Chronic Obstructive Pulmonary Disease, Lung Disease | Phase 2 | Completed | AstraZeneca | 63 | 2010-10-01 | 2014-10-23 |
| The Effectiveness of BreatheMAX Breathing Device on Secretion Clearance BreatheMAX breathing device - Lung Disease | Phase 2 / Phase 3 | Unknown | Khon Kaen University | 14 | 2009-08-01 | 2010-03-23 |
| Fetal Tracheal Balloon Study in Diaphragmatic Hernia Fetal tracheal obstruction with detachable balloon (device) - Diaphragmatic Hernia, Lung Disease | Phase 2 | Terminated | Rhode Island Hospital | 3 | 2008-09-01 | 2017-05-30 |
| Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients EPI-hNE4, Placebo - Fibrosis, Lung Disease | Phase 2 | Completed | Debiopharm International SA | 84 | 2006-07-01 | 2008-06-24 |
| Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Imatinib Mesylate (Gleevec) - Idiopathic Pulmonary Fibrosis, Lung Disease | Phase 2 / Phase 3 | Completed | Daniels, Craig E., M.D. | 120 | 2003-04-01 | 2005-10-05 |
| An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) interferon-gamma 1b - Lung Disease, Pulmonary Fibrosis | Phase 2 | Completed | InterMune | 210 | 2002-09-01 | 2007-11-06 |
| Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation nitric oxide for inhalation, Oxygen - Lung Disease, Hypoxemia | Phase 1 / Phase 2 | Terminated | Mallinckrodt | 7 | 2002-05-01 | 2016-10-19 |
| Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide Inhaled Nitric Oxide - Pulmonary Hypertension, Lung Disease | Phase 2 | Terminated | Mallinckrodt | 7 | 2002-04-01 | 2016-09-09 |
Lung Diseases (16) · Respiration Disorders (4) · Pulmonary Disease, Chronic Obstructive (3) · Pulmonary Fibrosis (3) · Respiratory Tract Diseases (3) · Carcinoma, Non-Small-Cell Lung (2) · Idiopathic Pulmonary Fibrosis (2) · Lung Neoplasms (2) · Acidosis, Respiratory (1) · Anemia, Sickle Cell (1) · Bronchial Neoplasms (1) · Bronchiectasis (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Emphysema (1)
Respiratory Tract Diseases (13) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (8) · Chronic Disease (3) · Disease Attributes (3) · Lung Diseases, Obstructive (3) · Bronchial Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Fibrosis (2) · Genetic Diseases, Inborn (2) · Lung Diseases, Interstitial (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Endothelium-Dependent Relaxing Factors (2) · Imatinib Mesylate (1) · Inhalation (1) · Interferon-gamma (1) · N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide (1) · Nitric Oxide (1) · Oxygen (1) · camrelizumab (1) · depelestat (1)
AstraZeneca (3) · Mallinckrodt (2) · Daniels, Craig E., M.D. (1) · Debiopharm International SA (1) · Healeon Medical Inc (1) · Intellia Therapeutics (1) · InterMune (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Khon Kaen University (1) · Pfizer (1) · Rhode Island Hospital (1) · Royal Marsden NHS Foundation Trust (1) · University of Edinburgh (1)
United States (6) · United Kingdom (3) · China (2) · Germany (2) · Italy (2) · Poland (2) · Spain (2) · Australia (1) · Bulgaria (1) · Czechia (1) · France (1) · Honduras (1) · Hong Kong (1) · Israel (1) · New Zealand (1)
Bengt Larsson (1) · Bengt Larsson,, M.B (1) · Chulee CU Jones, Philosophy (1) · Craig E Daniels, MD (1) · Dr Julia Riley (1) · Francois I Luks, MD, PhD (1) · Glenn C. Terry, MD (1) · Javier Szwarcberg, MD (1) · Joanna Marks-Konczalik, MD, PhD (1) · Joseph Lasky, MD (1) · Kev Dhaliwal, MRCP PhD (1) · Robert W Alexander, MD (1) · Steven H Abman, MD (1)
PMID 16235359, PMID 16565429, PMID 16636091, PMID 16690673, PMID 17132052, PMID 17507545, PMID 18073405, PMID 19183804, PMID 20007927, PMID 21975749, PMID 22314182, PMID 22761482, PMID 22793939, PMID 22793945, PMID 23074435, PMID 23076942, PMID 23235687, PMID 23256721, PMID 23364286, PMID 2337756, PMID 23992090, PMID 24563632, PMID 24615270, PMID 25450456, PMID 26103995, PMID 34668977
2025 (1)